Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine versus escitalopram in major depressive disorder with brain-gut axis assessment
ChiCTR1900024858Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vortioxetine and escitalopram in major depressive disorder (MDD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Psychological assessment scale at 24 weeks and Functional magnetic resonance imaging at 24 weeks. Started Aug 2019; status: recruiting.
02
Drugs
vortioxetineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1900024858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024858.